Research
Filter News
Found 146,432 articles
-
Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)
12/26/2023
Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces positive results from a pivotal clinical study for its proprietary Valacyclovir Oral Suspension.
-
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
12/26/2023
Oncternal Therapeutics, Inc. updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.
-
Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping
12/26/2023
Bionano Genomics, Inc. announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping to a combined workflow of chromosomal microarray analysis and karyotyping.
-
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its IRB to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
12/26/2023
RetinalGeniX™ Technologies Inc., announced that it has contracted with MEDsan, Inc. to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration, which was previously announced on October 30, 2023.
-
Now designated as a Tech Hub by the White House, Alabama’s nonprofit Southern Research is winnowing its focus and investing in healthcare solutions.
-
Eli Lilly has signed a multi-year contract with animal genomics biotech Fauna Bio to use its artificial intelligence platform to discover drug targets for obesity in a deal worth nearly half a billion dollars.
-
OliX Pharmaceuticals Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug
12/22/2023
OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has received approval from the Alfred Human Research Ethics Committee (HREC) to conduct a Phase 1 clinical trial of drug candidate OLX75016 (the candidate of OLX702A) for the treatment of non-alcohol steatohepatitis (NASH).
-
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
12/22/2023
Tyra Biosciences, Inc. today announced that it has initiated the SURF201 Phase 1 study of TYRA-200 and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300.
-
First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA
12/22/2023
Clarity Pharmaceuticals is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)1, at the Urology Cancer Center / XCancer Omaha, NE.
-
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
12/22/2023
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in ORION, a randomized, double-blind, placebo-controlled Phase 3 clinical trial of AMX0035.
-
Kansas City Proton Institute Begins Cancer Treatments with Advanced MEVION S250i Proton Therapy System
12/22/2023
Kansas City Proton Institute (KCPI), the first physician-led proton therapy center in the Midwest, and Mevion Medical Systems announced today that the first four patients were treated at Kansas City Proton Institute on Dec. 19, with the MEVION S250i Proton Therapy System® .
-
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
12/22/2023
Theseus Pharmaceuticals, Inc. today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock.
-
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
12/22/2023
AlloVir, Inc. today provided an update on its three Phase 3 clinical trials with posoleucel.
-
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
12/21/2023
MediWound Ltd. announced the publication of a peer-reviewed paper, titled “An Open-label, Proof of Concept Study, Assessing the Effects of Bromelain-Based Enzymatic Debridement on Biofilm and Microbial Loads in Patients with Venous Leg and Diabetic Foot Ulcers” in the December 2023 issue of WOUNDS Journal.
-
Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid Disorders
12/21/2023
SOPHiA GENETICS announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area.
-
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
12/21/2023
Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.
-
Bedrock Bioscience Announces Groundbreaking Medical Study Published in Prestigious Journal
12/21/2023
Bedrock Bioscience is thrilled to announce the publication of a groundbreaking medical study in the esteemed International Journal of Clinical Medicine.
-
Pressure BioSciences' Celebrates Second Groundbreaking Article Published This Month on its Transformative, Patented UltraShear Technology Processing Platform
12/21/2023
Pressure BioSciences, Inc. today announced the publication of a powerful visionary article in the respected industry trade magazine "Food Technology" published by the Institute of Food Technologists ("IFT").
-
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
12/21/2023
Matinas BioPharma Holdings, Inc. announces receipt of written feedback from U.S. Food and Drug Administration (FDA) on its proposed revised protocol for a Phase 3 study of MAT2203 in patients with invasive aspergillosis with limited or no treatment options.
-
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
12/21/2023
Arch Biopartners Inc. announced today that it received approval in Turkey from the Kocaeli University Clinical Research Ethics Committee to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).